Not a good buy right now: trend is bearish (SMA_200 > SMA_20 > SMA_5) and price remains below the key pivot (1.865), indicating sellers still control the tape.
Despite being near-term oversold (RSI_6 ~28) and close to support (S1 1.342), there is no confirmed reversal signal; an impatient entry here is effectively trying to catch a falling knife.
Fundamentals in the latest reported quarter (2024/Q4) show severe YoY profit deterioration (Net Income -85.6%, EPS -77.8%) with revenue shown as 0, which undermines confidence in a durable rebound.
Pattern-based odds provided: only 40% chance of modest gains (next day +0.34%, next week +5.44%, next month +12.49%), which is not a strong edge for an immediate entry.
Positive Catalysts
could support narrative and future adoption if it translates into measurable revenue.
and oversold RSI can fuel short-lived relief bounces if broader selling pressure fades.
Neutral/Negative Catalysts
Strong bearish trend (moving-average stack) and sub-pivot trading keep the primary trend downward.
Latest quarter profitability collapsed YoY (Net Income -85.6%, EPS -77.8%), and revenue is reported as 0 (whether tiny or missing, it reads as extremely weak).
No supportive positioning signals: hedge funds and insiders show “Neutral” (no accumulation signal).
No Intellectia buy signals today (AI Stock Picker / SwingMax), removing a key tactical reason to buy immediately.
Financial Performance
Latest quarter: 2024/Q4.
Revenue: reported as 0, up 0.00% YoY (effectively no demonstrated top-line growth in the snapshot).
Profitability: Net Income 101,471, down -85.60% YoY.
Earnings power: EPS 0.02, down -77.78% YoY.
Overall read-through: sharp deterioration in earnings momentum; not supportive of an immediate buy without clear evidence of re-acceleration.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so there is no visible Wall Street consensus shift to support a near-term buy thesis.
Practical takeaway: without upgrades/target raises to counterbalance the weak technicals and weak quarter, the risk/reward skews against buying right now.
Wall Street analysts forecast GIBO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GIBO is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast GIBO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GIBO is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.